MX2020002889A - Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo. - Google Patents

Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo.

Info

Publication number
MX2020002889A
MX2020002889A MX2020002889A MX2020002889A MX2020002889A MX 2020002889 A MX2020002889 A MX 2020002889A MX 2020002889 A MX2020002889 A MX 2020002889A MX 2020002889 A MX2020002889 A MX 2020002889A MX 2020002889 A MX2020002889 A MX 2020002889A
Authority
MX
Mexico
Prior art keywords
methods
disubstituted
pyrazolyl steroid
steroid
pyrazolyl
Prior art date
Application number
MX2020002889A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Jay Kanes
James J Doherty
Jeffrey M Jonas
Inderjit Kaul
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2020002889A publication Critical patent/MX2020002889A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020002889A 2017-09-14 2018-09-14 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo. MX2020002889A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762558703P 2017-09-14 2017-09-14
US201862624680P 2018-01-31 2018-01-31
US201862624678P 2018-01-31 2018-01-31
US201862653189P 2018-04-05 2018-04-05
PCT/US2018/051048 WO2019055764A1 (en) 2017-09-14 2018-09-14 C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME

Publications (1)

Publication Number Publication Date
MX2020002889A true MX2020002889A (es) 2020-10-01

Family

ID=65723895

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020002889A MX2020002889A (es) 2017-09-14 2018-09-14 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo.
MX2023010064A MX2023010064A (es) 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2023010063A MX2023010063A (es) 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023010064A MX2023010064A (es) 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2023010063A MX2023010063A (es) 2017-09-14 2020-03-13 Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.

Country Status (9)

Country Link
US (3) US20220110949A1 (enExample)
EP (3) EP4218767A1 (enExample)
JP (3) JP2020534270A (enExample)
AU (2) AU2018334214A1 (enExample)
CA (1) CA3075872A1 (enExample)
IL (2) IL303083A (enExample)
MX (3) MX2020002889A (enExample)
TW (2) TW201919642A (enExample)
WO (1) WO2019055764A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US20170233433A1 (en) * 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use

Also Published As

Publication number Publication date
US20250387414A1 (en) 2025-12-25
JP2023038310A (ja) 2023-03-16
MX2023010063A (es) 2023-09-06
EP4218767A1 (en) 2023-08-02
EP3681510A1 (en) 2020-07-22
CA3075872A1 (en) 2019-03-21
JP2020534270A (ja) 2020-11-26
MX2023010064A (es) 2023-09-06
EP4696301A3 (en) 2026-04-29
AU2024205601A1 (en) 2024-08-29
TW201919642A (zh) 2019-06-01
EP4696301A2 (en) 2026-02-18
WO2019055764A1 (en) 2019-03-21
US20230201224A1 (en) 2023-06-29
JP2024107137A (ja) 2024-08-08
IL303083A (en) 2023-07-01
IL273126A (en) 2020-04-30
AU2018334214A1 (en) 2020-03-26
TW202339764A (zh) 2023-10-16
US20220110949A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2023010063A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
MX2016017288A (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
MY179696A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
EA033689B9 (ru) Ингибиторы g12c kras
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
NZ709635A (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12016502353A1 (en) Pharmaceutical composition
MY203645A (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.